Charles River Laboratories International, Inc. (CRL)
$
178.14
-0.80 (-0.45%)
Key metrics
Financial statements
Free cash flow per share
11.7702
Market cap
8.8 Billion
Price to sales ratio
2.1751
Debt to equity
0.8308
Current ratio
1.3604
Income quality
-12.1369
Average inventory
284.9 Million
ROE
-0.0201
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Charles River Laboratories International, Inc. is a prominent non-clinical contract research organization that offers a range of services, including drug discovery, non-clinical development, and safety testing across various global markets, including the United States, Europe, Canada, and the Asia Pacific. The cost of revenue for the company is $2,718,168,000.00 showcasing its production and operational expenses that support its comprehensive service offerings. With an operating income ratio of 0.06 the company's operational profitability margin reflects its ability to maintain efficiency in its business activities. Additionally, the company incurred an interest expense of $126,288,000.00 which indicates its debt servicing obligations and financial commitments. The total costs and expenses for the company amount to $3,822,642,000.00 reflecting its overall spending in pursuit of excellence in research services. Furthermore, the gross profit ratio is 0.33 which assesses the efficiency of the company's production and sales operations, underscoring its strategic management practices and financial health. Moving forward, the stock is reasonably priced at $155.39 appealing to a broad range of investors seeking opportunities in the market. The stock has an average trading volume of 1,035,856.00 indicating moderate liquidity, which is favorable for both institutional and retail investors. With a mid-range market capitalization of $8,767,171,501.00 the company is recognized as a steady performer within the competitive landscape. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative approaches and extensive portfolio of services. Moreover, it belongs to the Healthcare sector, driving innovation and growth that enhance its reputation and stability in the industry as it responds to evolving market needs.
Is Charles River Laboratories International, Inc. (CRL) a good investment?
Investing in Charles River Laboratories International, Inc. (CRL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Charles River Laboratories International, Inc. (CRL)'s stock forecast?
Analysts predict Charles River Laboratories International, Inc. stock to fluctuate between $91.86 (low) and $203.01 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Charles River Laboratories International, Inc.'s market capitalization?
As of 2025-11-28, Charles River Laboratories International, Inc.'s market cap is $8,767,171,501, based on 49,215,064 outstanding shares.
How does Charles River Laboratories International, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Charles River Laboratories International, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Charles River Laboratories International, Inc. (CRL) stock?
To buy Charles River Laboratories International, Inc. (CRL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CRL. Place an order (Market, Limit, etc.).
What is the best time to invest in Charles River Laboratories International, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Charles River Laboratories International, Inc. perform in the last earnings report?
Revenue: $4,049,989,000 | EPS: $0.20 | Growth: 0%.
Where can I find Charles River Laboratories International, Inc.'s investor relations reports?
Visit https://www.criver.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Charles River Laboratories International, Inc.?
You can explore historical data from here
What is the all-time high and low for Charles River Laboratories International, Inc. stock?
All-time high: $460.21 (2021-09-24) | All-time low: $91.86 (2025-04-11).
What are the key trends affecting Charles River Laboratories International, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Charles River Laboratories International, Inc. ( CRL ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - Chairman, President & CEO Michael Knell - Interim CFO, Corporate Senior VP & Chief Accounting Officer Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division David Windley - Jefferies LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Justin Bowers - Deutsche Bank AG, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Michael Ryskin - BofA Securities, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Max Smock - William Blair & Company L.L.C.
benzinga.com
Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company's strategic review.
seekingalpha.com
Charles River Laboratories remains a "Hold" as strategic review yields minimal change and a sale is unlikely. CRL faces slow organic growth, shrinking backlog, and ongoing pressure in its core DSA segment, with limited near-term demand recovery. Cost-cutting, selective divestitures, and a new $1 billion buyback authorization offer some support, but growth headwinds persist.
reuters.com
Contract drug developer Charles River Laboratories on Wednesday raised its annual profit forecast after posting strong third-quarter results, helped by stabilized demand for its drug discovery and development services from biotech clients.
zacks.com
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
zacks.com
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
benzinga.com
Charles River Laboratories International Inc. (NYSE:CRL) is entering a critical point in its 18-phase Adhishthana cycle. The stock currently sits in Phase 17 on the weekly chart, with Phase 18, its final phase, set to begin on October 20.
businesswire.com
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Chief Financial Officer Transition.
zacks.com
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
See all news
